A meta-analysis of mood stabilizers for Alzheimer's disease

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 30, Issue 5, 2010, Pages 652-658

  Xiao, Haibing ^a   Su, Ying ^a   Cao, Xu ^b   Sun, Shenggang ^a   Liang, Zhihou ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CENTRAL HOSPITAL OF WUHAN   (China)

Author keywords

Alzheimer's disease; behavioral and psychological symptoms; meta analysis; mood stabilizers

Indexed keywords

CARBAMAZEPINE; LITHIUM; TRANQUILIZER; VALPROIC ACID;

AGED; ALZHEIMER DISEASE; ARTICLE; FEMALE; HUMAN; MALE; META ANALYSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; ALZHEIMER DISEASE; ANTIMANIC AGENTS; CARBAMAZEPINE; FEMALE; HUMANS; LITHIUM; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VALPROIC ACID;

EID: 78649804496     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-010-0559-5     Document Type: Article

References (38)

1. J.S. Paulsen D.P. Salmon L.J. Thal, et al. 2000 Incidence of and risk factors for hallucinations and delusions in patients with probable AD Neurology 54 10 1965 1971 1:STN:280:DC%2BD3c3osVWgtQ%3D%3D 10822438
2. R.E. Tractenberg M.F. Weiner L.J. Thal 2002 Estimating the prevalence of agitation in community-dwelling persons with Alzheimer's disease J Neuropsychiatry Clin Neurosci 14 1 11 18 11884649
3. Alexopoulos GS, Silver JM, Kahn DA, et al. Treatment of agitation in older persons with dementia. The Expert Concensus Panel for agitation in dementia. Postgrad Med, 1998,Spec No:1-88
4. G.S. Alexopoulos J. Streim D. Carpenter, et al. 2004 Using antipsychotic agents in older patients J Clin Psychiatry 65 Suppl2 5 104 14994733
5. Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev, 2009,(3):CD003945
6. A.R. Jadad R.A. Moore D. Carroll, et al. 1996 Assessing the quality of reports of randomized clinical trials: Is blinding necessary Control Clin Trials 17 1 1 12 1:STN:280:DyaK28zgvVCmug%3D%3D 10.1016/0197-2456(95)00134-4 8721797 (Pubitemid 26120810)
7. A.P. Porsteinsson P.N. Tariot R. Erb, et al. 2001 Placebo-controlled study of divalproex sodium for agitation in dementia Am J Geriatr Psychiatry 9 1 58 66 1:STN:280:DC%2BD3M3htFGqtw%3D%3D 11156753
8. R.C. Sival P.M. Haffmans P.A. Jansen, et al. 2002 Sodium valproate in the treatment of aggressive behavior in patients with dementi-A randomized placebo controlled clinical trial Int J Geriatr Psychiatry 17 6 579 585 10.1002/gps.653 12112183 (Pubitemid 34678711)
9. P.N. Tariot L.S. Schneider J.E. Mintzer, et al. 2001 Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial Curr Ther Rev 62 51 67 1:CAS:528:DC%2BD3MXhtlKhurw%3D 10.1016/S0011-393X(01)80042-4 (Pubitemid 32493031)
10. O.H. Sommer O. Aga M. Cvancarova, et al. 2009 Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia Dement Geriatr Cogn Disord 27 2 155 163 1:CAS:528:DC%2BD1MXis12gu74%3D 10.1159/000199236 19182483
11. P.N. Tariot R. Erb C.A. Podgorski, et al. 1998 Efficacy and tolerability of carbamazepine for agitation and aggression in dementia Am J Psychiatry 155 1 54 61 1:STN:280:DyaK1c%2FpsV2isQ%3D%3D 9433339
12. P.N. Tariot R. Erb A. Leibovici, et al. 1994 Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study J Am Geriatr Soc 42 11 1160 1166 1:STN:280:DyaK2M%2Flt1anuw%3D%3D 7963202
13. M.R. Lemke 1995 Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics J Clin Psychiatry 56 8 354 357 1:STN:280:DyaK2Mzmt1Ojsg%3D%3D 7635851
14. R.P. Gleason L.S. Schneider 1990 Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics J Clin Psychiatry 51 3 115 118 1:STN:280:DyaK3c7ntVyqtQ%3D%3D 1968457
15. H. Hampel M. Ewers K. Bürger, et al. 2009 Lithium trial in Alzheimer's disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study J Clin Psychiatry 70 6 922 931 1:CAS:528:DC%2BD1MXhsFentbbL 10.4088/JCP.08m04606 19573486
16. T. Leyhe G.W. Eschweiler E. Stransky, et al. 2009 Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease J Alzheimers Dis 16 3 649 656 1:CAS:528:DC%2BD1MXivVShsr0%3D 19276559
17. N. Herrmann K.L. Lanctôt L.S. Rothenburg, et al. 2007 A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease Dement Geriatr Cogn Disord 23 2 11611 11619 10.1159/000097757 (Pubitemid 46105702)
18. A. Macdonald K. Briggs M. Poppe, et al. 2008 A feasibility and tolerability study of lithium in Alzheimer's disease Int J Geriatr Psychiatry 23 7 704 711 10.1002/gps.1964 18181229
19. J.T. Olin L.S. Fox S. Pawluczyk, et al. 2001 A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease Am J Geriatr Psychiatry 9 4 400 405 1:STN:280: DC%2BD3MnovFGjtw%3D%3D 11739066
20. L.A. Profenno L. Jakimovich C.J. Holt, et al. 2005 A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease Curr Alzheimer Res 2 5 553 558 1:CAS:528:DC%2BD2MXht1CgtLrO 10.2174/ 156720505774932205 16375658
21. P.N. Tariot R. Raman L. Jakimovich, et al. 2005 Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial Am J Geriatr Psychiatry 13 11 942 949 16286437
22. G. Mckhann D. Drachman M. Folstein, et al. 1984 Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease Neurology 34 7 939 944 1:STN:280:DyaL2c3ks1altQ%3D%3D 6610841
23. J.L. Cummings M. Mega K. Gray, et al. 1994 The Neuropsyc iatric Inventory: comprehensive assessment of psychopat hology in dementia Neurology 44 12 2308 2314 1:STN:280:DyaK2M%2FotlWisw%3D%3D 7991117
24. L.S. Schneider K.S. Dagerman P. Insel 2005 Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials JAMA 294 15 1934 1943 1:CAS:528:DC%2BD2MXhtFCitLnK 10.1001/jama.294.15.1934 16234500 (Pubitemid 41464695)
25. N. Herrmann K.L. Lanctôt 2005 Do atypical antipsychotics cause stroke? CNS Drugs 19 2 91 103 10.2165/00023210-200519020-00001 15697324 (Pubitemid 40321762)
26. P.N. Tariot R. Loy J.M. Ryan, et al. 2002 Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales Adv Drug Deliv Rev 54 12 1567 1577 1:CAS:528:DC%2BD38XovFemt7c%3D 10.1016/S0169-409X(02)00153-9 12453674 (Pubitemid 35346831)
27. W. Löscher 1999 Valproate: a reappraisal of its pharmacody namic properties and mechanisms of action Prog Neurobiol 58 1 31 59 10.1016/S0301-0082(98)00075-6 10321796 (Pubitemid 29166878)
28. R.J. Mark J.W. Ashford Y. Goodman, et al. 1995 Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology Neurobiol Aging 16 2 187 198 1:CAS:528:DyaK2MXkvVGgsr8%3D 10.1016/0197-4580(94)00150-2 7777136
29. N.B. Farber J.W. Newcomer J.W. Olney 1998 The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease Prog Brain Res 116 421 437 1:CAS:528:DyaK1cXotVCmu7g%3D 10.1016/S0079-6123(08)60453-7 9932393
30. C.X. Gong F. Liu I. Grundke-Iqbal, et al. 2005 Post-translational modifications of tau protein in Alzheimer's disease J Neural Transm 112 6 813 838 1:CAS:528:DC%2BD2MXjvVSqt7o%3D 10.1007/s00702-004-0221-0 15517432 (Pubitemid 40655573)
31. X. Run Z. Liang L. Zhang, et al. 2009 Anesthesia induces phosphorylation of tau J Alzheimers Dis 16 3 619 626 1:CAS:528:DC%2BD1MXivVShsrw%3D 19276556
32. Z. Liang F. Liu K. Iqbal, et al. 2009 Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage J Alzheimers Dis 17 3 531 539 1:CAS:528:DC%2BD1MXotVemtL4%3D 19363259
33. H. Wang H. Zhao Y. Ye, et al. 2010 Focal cerebral ischemia induces Alzheimer's disease-like pathological change in rats J Huazhong Univ Sci Technol [Med Sci] 30 1 29 36 10.1007/s11596-010-0106-4
34. J. Zhou J. Chen Y. Feng 2006 Effect of truncated-ApoE4 overexpression on tau phosphorylation in cultured N2a cells J Huazhong Univ Sci Technol [Med Sci] 26 3 272 274 1:CAS:528:DC%2BD28XhtVCmt7nK 10.1007/BF02829548
35. M. Tajes J. Gutierrez-cuesta J. Folch, et al. 2008 Lithium treatment decreases activities of tau kinases in a murine model of senescence J Neuropathol Exp Neurol 67 6 612 623 1:CAS:528:DC%2BD1cXotVantL4%3D 10.1097/NEN.0b013e3181776293 18520779 (Pubitemid 351787087)
36. K. Ghosal D.L. Vogt M. Liang, et al. 2009 Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain Proc Natl Acad Sci USA 106 43 18367 18372 1:CAS:528:DC%2BD1MXhsVWrtr3N 10.1073/pnas.0907652106 19837693
37. P. Cohen S. Frame 2001 The renaissance of GSK3 Nat Rev Mol Cell Biol 2 10 769 776 1:CAS:528:DC%2BD3MXnvVajsLc%3D 10.1038/35096075 11584304 (Pubitemid 33679839)
38. G. Chen L.D. Huang Y.M. Jiang, et al. 1999 The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3 J Neurochem 72 3 1327 1305 1:CAS:528:DyaK1MXhsFWgtrs%3D 10.1046/j.1471-4159.2000.0721327.x 10037507 (Pubitemid 29085050)